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Objective: We hypothesized that most relapses in patients with esophageal cancer having neoadjuvant chemo-
radiation therapy would occur outside of the surgical and radiation fields.
Methods: Recurrence patterns, time to recurrence, and median survival were examined in 267 patients who had
esophagectomy after neoadjuvant chemoradiation therapy at Johns Hopkins over 19 years.
Results:Of 267 patients, 82 (30.7%) showed complete response to neoadjuvant therapy,with 108 (40.4%) and 77
(28.8%) showing partial response or no response, respectively. Recurrence developed in 84 patients (patients with
complete response 18/82, 21.4%; patients with partial response 39/108, 36.1%; patients with no response 27/77,
35.1%; P ¼ .055, respectively). Most patients had recurrences at distant sites (65/84;77.4%) regardless of path-
ologic response, and subsequent survival was brief (median 8.37 months). Median disease-free survival was short
(10 months) and did not differ based on recurrence site for patients with partial response or no response, but was
longer for patients with complete response with distant recurrence, whose median disease-free survival was 27.3
months (P¼ .008). Bymultivariate analysis, no other factor except for pathologic response to neoadjuvant therapy
was associated with disease recurrence or death. Patients with partial response or no response were 1.97 and 2.23
times more likely to have recurrence than patients with complete response (P¼ .024 and P¼ .012, respectively).
Conclusions:Most esophageal cancer recurrences after neoadjuvant therapy and surgery are distant, and survival
time after recurrence is short regardless of pathologic response. Fewer patients achieving complete response had
recurrences, and distant recurrences in these patients manifest later than in patients showing partial response and
those showing no response. Only pathologic response is significantly associated with disease recurrence, suggest-
ing that tumor biology and chemosensitivity are critical in long-term patient outcome. (J Thorac Cardiovasc Surg
2009;138:1309-17)
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doi:10.1016/j.jtcvs.2009.07.069The Journal of Thoracic and CMost surgical candidates with esophageal cancer present
with regional nodal metastases, or stage III disease.1 Histor-
ically, the primary curative treatment was a total or partial
esophagectomy and lymph node dissection, with resultant
5-year survival rates ranging between 15% and 20%.1 After
encouraging preliminary data in the late 1980s, and our own
investigations, neoadjuvant chemoradiotherapy in combina-
tion with surgery became the mainstay of treatment at our in-
stitution over the last 19 years. This trimodality approach is
now widely accepted clinical practice.2,3
Despite this widespread use, especially in North America,
short- and long-term patient outcome data after neoadjuvant
therapy plus surgery have been conflicting.4,5 Importantly,
however, the 25% to 30% of patients with a pathologic
complete response (CR) after this therapy have significantly
improved 5-year survival rates compared with other treat-
ment modalities for advanced esophageal cancer.4-7 How-
ever, it is also clear that about 30% of patients with
a pathologic CR still have recurrences and die from meta-
static esophageal cancer.8 In these patients with a pathologicardiovascular Surgery c Volume 138, Number 6 1309
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CR ¼ complete response
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CR, in particular, little is known about the impact of neoad-
juvant chemoradiation on the timing and patterns of recur-
rent esophageal cancer or on the overall survival of these
patients with recurrent disease.
We hypothesized that chemoradiation plus surgery would
lead to improved local tumor control compared with surgery
alone and that most relapses would occur outside the surgi-
cal and radiation fields. We also hypothesized that recur-
rence would predominate in patients with chemoresistant
tumors that were not impacted by neoadjuvant chemoradia-
tion and surgery, and thus would occur relatively quickly.
We, therefore, examined if recurrence patterns, time to re-
currence, and overall median survival differed with patho-
logic response to neoadjuvant chemoradiotherapy.
METHODS
Data Source
This is a retrospective analysis using patient data collected from the
Johns Hopkins Hospital Multidisciplinary Esophageal Cancer Database,
which contains demographic and clinical data and outcome of patients
with esophageal cancer evaluated at Johns Hopkins Hospital between
January 1, 1989, and December 31, 2007. Data in the database were ob-
tained from patient hospital charts, as well as electronic and paper files.
Since 2000, periodic data audits have been performed by archival and on-
line chart reviews for quality assurance. These reviews have consistently
verified over 90% accuracy of the database with source materials.
Patient Outcome Data
Follow-up data and sites of tumor recurrence were determined by a sys-
tematic follow-up of any patients with incomplete data attained by letters,
E-mails, faxes, and phone calls to their referring physicians. In almost all
cases, recurrence was documented radiographically, but, in a few cases,
there was also pathologic assessment. All sites of first recurrence were re-
corded. These data were obtained from clinic charts with confirmation by
reviewing associated imaging and pathology reports. This study was ap-
proved by the Johns Hopkins Institutional Review Board, which exempted
the need for patient consent, and abides by Health Insurance Portability and
Accountability Act compliance standards.
Patient Population
Patient selection criteria included a biopsy-proven esophageal carcinoma
and a documented assessment by a thoracic surgeon, a medical oncologist,
a gastroenterologist, and a radiation oncologist at the Johns Hopkins Hospi-
tal. We identified 267 patients who had pretreatment clinical staging, neo-
adjuvant chemotherapy and/or radiotherapy, and an esophagectomy with
curative intent.
Race was self-reported as Caucasian, African-American, or other. For
ease of analysis, patients of other race were documented as minorities and
combined with the African-American patients. Clinical staging was deter-
mined at the time of initial evaluation and was available on all but 2 patients1310 The Journal of Thoracic and Cardiovascular Swho both showed complete response. All 267 patients had a recorded path-
ologic stage derived from the pathology record. Smoking history was avail-
able on all but 5 patients. Patients were identified as ever or never smokers
based on self-reporting. Ever smokerswere defined as thosewhohad smoked
100 tobacco cigarettes or more during their lifetime, and never smokers were
thosewho had smoked fewer than 100 cigarettes. Pack-year indexwas deter-
mined bymultiplying the average number of cigarette packs smoked per day
by the number of years smoked. The American Society of Anesthesiologists
5-grade classification systemwas used as an index of preoperative comorbid-
ity.9 Esophagectomies were performed as partial esophagectomies using the
transhiatal (81%), the 3-incision (15%), the Ivor Lewis (2%), or the thora-
coabdominal approach (2%; Table 1). During the length of the study, these 4
approaches were all used with concomitant mediastinal lymphadenectomy.
The median number of lymph nodes harvested was 15.
Neoadjuvant Chemoradiation and Pathologic
Response
To compare and control for multimodal preoperative and postoperative
therapy, we examined neoadjuvant chemo- and radiotherapy types and
doses as well as adjuvant chemotherapy. Neoadjuvant chemotherapy agents
were almost always given as platinum-based doublets and are stratified as
either with or without fluorouracil. Neoadjuvant radiotherapy dose was re-
corded as either<4400 cGy or4400 cGy. Postoperative adjuvant chemo-
therapy was recorded as either administered or not.
Pathologic response to neoadjuvant chemoradiation was based on our
previously described classification system and determined at the time of
pathologic examination of the surgical specimen.10 Briefly, patients were
identified as having a pathologic CR if no microscopic evidence of tumor
was found upon examination of both the resected esophageal specimen
and nodal tissues. Partial response (PR) described patients with persistence
of microscopic esophageal carcinoma in the resected surgical specimen but
their overall American Joint Committee on Cancer (AJCC)11 stage was
lower as compared with preoperative clinical staging. Nonresponse (NR)
described patients with either no change in AJCC stage between clinical
and pathologic staging, or progression of disease despite neoadjuvant ther-
apy. Of note, at our institution, we treat patients with stage IVA disease (lo-
cal lymph node involvement) with multimodality therapy. Preoperative
clinical staging was performed by compiling results from computed tomog-
raphy scans, esophageal endoscopic ultrasound, barium esophagrams, pos-
itron emission tomography scans (65% of patients), and in some patients,
exploratory laparoscopy.10
Recurrences
Time between diagnosis and surgery, length of stay after surgery, recur-
rence-free survival (time from surgery to disease recurrence), and overall
survival were calculated and reported. All patients in the data set were in-
cluded in consideration of disease recurrence (or disease progression for
the patients with no response to neoadjuvant chemoradiation) except 6 pa-
tients who were found at time of surgery to have metastatic stage IVA (2 pa-
tients with celiac lymph nodes) or IVB disease (2 patients with isolated liver
metastases, 1 patient with an omentalmetastasis, and 1 patient with supracla-
vicular disease). Note that these 6 patients still were aggressively resected
and local therapy applied to their metastatic site, and so they are included
in the larger cohort of 267 patients. All sites of tumor recurrence were re-
corded and categorized as the abdomen (excluding the liver), the liver, the
brain, bone, the chest (excluding the esophagus), the esophagus, and other.
Statistical Analysis
Comparison of continuous, categorical, and dichotomous variables was
performed using the Student t test and chi-square test for homogeneity.
Time to recurrence-free survival and all-cause mortality was modeled using
the Kaplan-Meier method, and the association of factors with time to recur-
rence and death was analyzed using the Cox proportional hazards model.
The model was adjusted by risk factors for recurrence and mortality thaturgery c December 2009
Meguid et al General Thoracic Surgery
G
T
STABLE 1. Characteristics of the study population by pathologic response (n ¼ 267)
Complete response, 82 (30.7%) Partial response, 108 (40.4%) No response, 77 (28.8%)
n % n % n % P value
Age at diagnosis (y), median and IQR 61 51–67z 61 51–67z 60 52–67z .773
Sex .002
Male 66 80.5 104 96.3 69 89.6
Female 16 19.5 4 3.7 8 10.4
Race .404
White 76 92.6 102 94.4 68 88.3
Black 3 3.7 4 3.8 7 9.1
Other 3 3.7 2 1.8 2 2.6
Smoked cigarettes* .952
Never 15 19.0 22 2.4 14 18.7
Ever 64 81.0 86 79.6 61 81.3
Pack-years smoked (y),* median and IQR 32.9 23.7–53.6z 35 15–50z 40 25–60z .284
ASA classification, median 3 3 3 .565
Histology <.001
Adenocarcinoma 54 65.9 96 88.9 58 75.3
Squamous cell 24 29.3 12 11.1 19 24.7
Carcinoma, NOS 4 4.8 0 .0 0 0.0
Clinical stagey <.001
IIA 29 36.3 11 1.2 33 42.9
IIB 9 11.2 15 13.9 15 19.4
III 35 43.8 61 56.5 23 29.9
IVA 7 8.7 21 19.4 6 7.8
Pathologic stage <.001
No evidence of disease 82 100 0 .0 0 0.0
I 0 0.0 30 27.8 0 0.0
IIA 0 0.0 60 55.6 27 35.0
IIB 0 0.0 13 12.0 9 11.7
III 0 0.0 5 4.6 35 45.5
IVA 0 0.0 0 .0 2 2.6
IVB 0 0.0 0 .0 4 5.2
Neoadjuvant chemotherapy .149
5-FU and platinum only 62 75.6 70 64.8 46 59.7
Non-5-FU/platinum 8 9.8 21 19.5 19 24.7
Course unknown 12 14.6 17 15.7 12 15.6
Neoadjuvant radiotherapy dose .137
<4,400 cGy 3 3.7 6 5.5 6 7.8
4,400 cGy 54 65.9 58 53.7 39 50.6
Dose unknown 25 30.4 43 39.8 28 36.4
No radiotherapy 0 0.0 1 1.0 4 5.2
Adjuvant chemotherapy .230
Received 19 23.2 26 24.1 11 14.3
Not received 63 76.8 82 75.9 66 85.7
Surgical procedure .522
Transhiatial 65 79.3 88 81.5 62 80.5
3-Incision 14 17.1 17 15.7 10 13.0
Ivor Lewis 3 3.6 1 0.9 2 2.6
Thoracoabdominal 0 0.0 2 1.9 3 3.9
Interval between diagnosis and
surgery, (days) median and IQR
91 82–108 94 82–110 90 78–110 .730
Postoperative stay, (days) median and IQR 9 8–14 9 8–10 8 7–11 .565
Overall survival, (mos) median and IQR 79.3 30.1–NR 30.6 14.8–94.9 18.6 11.0–40.8 .001
Overall survival after recurrence,
(mos) median and IQR
10.8 2.6–21.1 9.8 3.1–16.6 7.2 4.7–14.4 .707
ASA,American Society of Anesthesiologists; F-FU, fluorouracil; IQR, interquartile range;NOS, not otherwise specified;NR, not reached. *Available on 262 patients. yAvailable on
265 patients. zInterquartile range.The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 6 1311
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STABLE 2. First tumor recurrence site according to pathologic response status to neoadjuvant therapy (n ¼ 84)
Proportion of patients with recurrence from total cohort
Complete response (n ¼ 82) Partial response (n ¼ 108) No response (n ¼ 77)
n % n % n % P value
Overall recurrence 18 22.0 39 36.1 27 35.1 .055
Tumor site
Esophagus and mediastinum 5 27.2 8 20.5 6 22.2
Lung and pleura 4 22.2 7 17.9 4 14.8
Abdomen 5 27.7 9 23.0 4 14.8
Liver 1 5.5 6 15.3 6 22.2
Brain 1 5.5 2 5.1 2 7.4
Bone 2 11.1 7 17.9 5 18.5included patient sex, histology, and clinical stage. Crude hazard ratios and
corresponding 95% confidence intervals are reported. All hazard ratios are
presented as independent variables and then further adjusted for specified
variables and are presented as adjusted hazard ratios.
Overall survival was defined as time from date of surgical therapy to
death or last follow-up. Disease-free survival, defined as time from date
of surgical therapy to first recurrence or last follow-up, is used interchange-
ably with "recurrence-free" survival in the article.
Differences between Kaplan-Meier survival curves were estimated using
the log-rank test. Statistical analysis was performed using the software pack-
age STATA 10.0 (StataCorp, College Station, Tex).
RESULTS
Table 1 shows the clinicopathologic characteristics of all
267 patients. Median age was 60 years (interquartile range,
51–67) with 239 (89.5%) being men. The racial distribu-
tion included 246 (92.2%) Caucasians, 14 (5.2%)
African-Americans, and 7 (2.6%) of other race. Most pa-
tients, 211 (80.5%), were ever smokers (87 current
smokers; 124 former smokers) with a median pack-years
smoked of 35. Adenocarcinoma was the reported histology
for 208 (77.9%) patients, squamous cell histology for 55
(20.6%) patients, and 4 (1.5%) patients with carcinoma,
not otherwise specified. Median time between diagnosis
and surgery was not different between response groups,
nor was there a difference in median hospital length of
stay. In patients with known chemotherapy regimens and
radiation doses, the majority received fluorouracil and plat-
inum neoadjuvant chemotherapy (178/226, 78.8%), along
with at least 4400 cGy (151/166, 91%) of neoadjuvant ra-
diation. Only 56/267 (21.0%) of patients received adjuvant
chemotherapy.Of 267 patients, 82 (30.7%) had CR to neoadjuvant ther-
apy, 108 (40.4%) patients had PR, and 77 (28.8%) had NR.
On univariate analysis, PR, CR, and NR cohorts differed sig-
nificantly by sex, tumor histology, and initial clinical stage
(Table 1). Esophageal malignancy recurred in a total of 84
patients (31.5%). There was a strong trend toward a statisti-
cally significant difference in frequency of esophageal recur-
rence between response groups (CR: 18/82, 22.%; PR: 39/
108, 36.1%; and NR: 27/77, 35.5%; P ¼ .055; Table 2).
The distributions of patterns of first tumor recurrence for
the individual organ sites between the 3 different pathologic
response groups are also presented in Table 2. Although
there seems to be proportionately fewer bone/liver metasta-
ses for the patients in the CR group, there is no significant
difference in site of recurrences between response groups.
When recurrence sites were grouped as either within the ra-
diation field (including esophagus and mediastinum) versus
outside the field (all other sites of recurrence), again there
was no significant difference in patterns of recurrence ac-
cording to the pathologic response group (Table 3).
Median disease-free survival differed significantly when
stratified by response group and whether or not the first
site of recurrence was locoregional or distant (Table 4).
All recurrences occurred within a median time of 10 months
postoperatively except for distant recurrences in patients
who had a CR to neoadjuvant chemoradiation. In these pa-
tients, the median disease-free survival was 27.3 months
(P ¼ .008). Thus, these data suggest that neoadjuvant che-
moradiation delayed recurrence significantly and as well
fewer patients failed (P ¼ .055). Figure 1 showing freedomTABLE 3. Proportion of first recurrences within and outside the radiation field according to pathologic response (n ¼ 84)
Proportion recurred
Complete response (n ¼ 18) Partial response (n ¼ 39) No response (n ¼ 27)
n % n % n % P value
Radiation field .829
Within radiation field 5 27.8 8 20.5 6 22.2
Outside radiation field 13 72.2 31 79.4 21 77.8
1312 The Journal of Thoracic and Cardiovascular Surgery c December 2009
Meguid et al General Thoracic SurgeryTABLE 4. Median disease-free survival (in months) of patients with recurrence (n ¼ 84)
Complete response Partial response No response
Median IQR Median IQR Median IQR P value
Within radiation field 5.8 4.7–9.3 7.1 3.5–18 8.5 7.5–62.3 .604
Outside radiation field 27.3 12.3–31.1 5.7 3.9–15.8 9.1 6.9–14.5 .008
IQR, Interquartile range.G
T
Sfrom recurrence again underscores the fact that patients with
CR have a significantly longer disease-free interval than pa-
tients with PR and NR (P ¼ .01).
This impact of chemoradiation in preventing recurrence
was of sufficient magnitude also to impact survival. The me-
dian overall survival was greatest for the CR cohort (79.3
months), which was significantly longer than that of the
PR (30.6 months) and NR cohorts (18.6 months), respec-
tively (P< .001). Kaplan-Meier overall survival estimates
of all 3 pathologic response groups are depicted in Figure 2,
showing a statistically significant difference in overall sur-
vival (all-cause mortality) at 5 years. Interestingly, early
mortality (<10 months) did not differ by pathologic re-
sponse group, with only patients surviving longer than 1
year showing significant differences in mortality by patho-
logic response to neoadjuvant therapy (Figure 2). The over-
all 5-year survival for patients with CR and PR who did not
recur is statistically longer than for those patients whose can-
cer recurred (Figures 3 and 4). Patients in the NR group who
did not progress with further disease had survival outcomes
as poor as those who showed clinical evidence of disease
progression (Figure 5). This is probably because if tumors
are aggressive enough to be recalcitrant to neoadjuvant che-
moradiation, little additional tumor burden is necessary to
cause eventual death.
After adjusting for sex, histology, and clinical stage in
a multivariate model, no other demographic or clinicopath-
ologic factor except for pathologic response to neoadjuvant
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FIGURE 1. Kaplan-Meier estimates of recurrence-free survival of patients
with esophageal cancer (n¼ 261) at the Johns Hopkins Hospital, according
to pathologic response at time of surgical resection.CR,Complete response;
NR, nonresponse; PR, partial response.The Journal of Thoracic and Ctherapy at time of surgical resection was associated with dis-
ease-free survival. Patients in the PR and NR groups were
1.97 and 2.23 times more likely to have disease recurrence
(P¼ .024 and P¼ .012, respectively; Table 5). Once disease
recurred, all deaths occurred within a year regardless of ini-
tial response groups and all deaths were cancer-related (data
not shown). Finally, the median overall survival of patients
with recurrence versus patients without recurrence was 21.2
months versus 65.2 months, respectively (P< .01).
DISCUSSION
We report on our institution’s experience with esophageal
cancer, examining survival outcomes and patterns of disease
recurrence after neoadjuvant chemoradiotherapy. For all 3
response groups, most recurrences were distant, suggesting
the important role of intensified local therapies to eradicate
local disease and prevent locoregional recurrence. By multi-
variate analysis, only pathologic response to neoadjuvant
chemotherapy is a significant factor in disease recurrence.
The implication of this finding is that, given eminent resect-
ability of the primary tumor, the esophageal tumor biology
with its intrinsic sensitivities to the correct chemoradiation
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FIGURE 2. Kaplan-Meier estimates of overall survival of patients with
esophageal cancer (n ¼ 267) at the Johns Hopkins Hospital, according to
pathologic response at time of surgical resection. The Kaplan-Meier esti-
mates for overall survival indicate that as the extent of pathologic response
to neoadjuvant therapy increases, there is a significant increase in the overall
survival of the patient. It is interesting to note, however, that in our observed
cohort, the degree of pathologic response to neoadjuvant therapy seemed
not to affect patients with early mortality (<10 months) but rather those
who survived more than 1 year. CR, Complete response; NR, nonresponse;
PR, partial response.ardiovascular Surgery c Volume 138, Number 6 1313
General Thoracic Surgery Meguid et al
G
T
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outcome. Patients showing complete response, even those
who eventually have recurrence with distant disease, experi-
enced the longest median recurrence-free survival time, and
moreover, patients with a complete response to neoadjuvant
therapy had significantly improved overall survival com-
pared with patients with partial response and those with no
response. The frequency of recurrence tended to be greater
for those showing no response and lowest for patients show-
ing complete response.
In patients with CR, tumors exhibited such a high degree
of chemoradiation sensitivity that not only the primary tu-
mor but also distant micrometastases were controlled by
the neoadjuvant therapy. It is possible that in patients in
the PR group with variable tumor sensitivity, the persistence
of distant micrometastases caused distant tumor recurrence.
In an aggressive cancer, such as esophageal cancer, any re-
maining distant metastasis after neoadjuvant therapy en-
sured that patients with PR had recurrences outside of the
treated field with the same virulence as those patients with
NR not affected by neoadjuvant therapy (Table 4).
These findings reinforce just how critical a CR can be to
a patient with esophageal cancer having neoadjuvant therapy
and surgery. The 5 patients who had CR and whose recur-
rence was local received no discernable benefit from chemo-
radiation, as the median disease-free interval of these 5
patients was not different from that of the patients who
had a PR or NR. This is in direct contrast to the 13 patients
who had CR and who recurred distantly after neoadjuvant
therapy and surgery, as these patients had late relapse,
with a median recurrence time of over 2 years. Presumably,
the micrometastatic disease present in these 13 patients with
CR had a molecular profile with some degree of chemosen-
sitivity to the preoperative chemotherapeutic regimen given,
which presumably delayed the eventual reemergence of dis-
tant macrometastases.
The demographic and histopathologic composition of our
cohort is representative of other large medical centers with
high-volume esophageal practices in the United States
over this period.6,7,12 Our percentages of patients with
esophageal cancer who had a CR, a PR, and NR and who re-
ceived neoadjuvant therapy is also very similar to that of
other groups6,7 despite small differences in definitions
used for codification of groups. The similarity of our results
to others validates the universal nature of our findings.
Although our data showed that locoregional recurrence
rates did not differ according to response groups (Table 3),
we do not think that these data can be extrapolated to support
the assertion that surgery alone may be effective at control-
ling local disease. Our 23% local recurrence rate for patients
having neoadjuvant chemoradiation closely resembles the
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FIGURE 3. Kaplan-Meier estimates of overall survival of patients with
esophageal cancer who had a complete pathologic response to neoadjuvant
therapy (n¼ 82) at the Johns Hopkins Hospital, according to whether or not
there was cancer recurrence following surgical resection.D-F,Disease-free;
R, recurrence.
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FIGURE 4. Kaplan-Meier estimates of overall survival of patients with
esophageal cancer who had a partial pathologic response to neoadjuvant
therapy (n ¼ 108) at the Johns Hopkins Hospital, according to whether or
not there was cancer recurrence following surgical resection. D-F, Dis-
ease-free; R, recurrence.
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FIGURE 5. Kaplan-Meier estimates of overall survival of patients with
esophageal cancer who had no pathologic response to neoadjuvant therapy
(n ¼ 71) at the Johns Hopkins Hospital, according to whether or not there
was cancer recurrence following surgical resection. D-F, Disease-free; R,
recurrence.1314 The Journal of Thoracic and Cardiovascular Surgery c December 2009
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STABLE 5. Crude and adjusted hazard ratios for the association between pathologic response and recurrence
Crude hazard ratio 95% CI P value Adjusted hazard ratio* 95% CI P value
Clinical response
Complete response 1.00 Referent 1.00 Referent
Partial response 2.13 1.22–3.74 0.008 1.97 1.10–3.57 .024
No response 2.26 1.24–4.13 0.008 2.23 1.20–4.17 .012
Age at diagnosis (y) 0.98 0.96–1.00 0.164
Sex
Male 1.00 Referent 1.00 Referent
Female 0.74 0.34–1.60 0.440 0.91 0.38–2.21 .840
Race
White 1.00 Referent
Black 1.58 0.58–4.34 0.369
Histology
Adenocarcinoma 1.00 Referent 1.00 Referent
Squamous cell 0.85 0.45–1.43 0.458 0.95 0.50–1.83 .887
ASA classification
2 1.00 Referent
3 0.97 0.50–1.88 0.925
4–5 0.8 0.22–2.91 0.734
Clinical stage
IIA 1.00 Referent 1.00 Referent
IIB 1.42 0.74–2.72 0.290 1.21 0.63–2.35 .565
III 1.21 0.72–2.04 0.469 1.19 0.68–2.07 .537
IVA 1.18 0.53–2.65 0.681 1.13 0.47–2.68 .787
Neoadjuvant chemotherapy
5-FU-based 1.00 Referent
Non-5-FU-based 0.90 0.53–1.51 0.684
Neoadjuvant radiotherapy
4400 cGy 1.00 Referent
<4400 cGy 0.47 0.15–1.52 0.209
Dose unknown 0.85 0.53–1.36 0.497
Smoked cigarettes
Never 1.00 Referent
Ever 1.09 0.63–1.88 0.755
Pack-years smoked 0.99 0.98–1.01 0.250
ASA, American Society of Anesthesiologists; CI, confidence interval; 5-FU, fluorouracil. *Adjusted for sex, histology, and clinical stage.19% local failure rate of the neoadjuvant chemoradiation
arm of the randomized clinical trial of Urba and colleagues13
conducted at the University of Michigan. Moreover, in both
the Michigan trial and the large, randomized US G-I Inter-
group trial, the locoregional disease recurrence rates for
the surgery alone control arms were 42% and 58%, respec-
tively.14,15 Importantly, our results therefore further corrob-
orate the point that neither surgery alone nor chemoradiation
alone is as effective as trimodality therapy in achieving local
disease control.
In multivariable regression analysis examining the like-
lihood of tumor recurrence, patients with a PR or NR to
neoadjuvant therapy were 1.97 and 2.23 times more likely
to develop tumor recurrence compared with patients with
a CR. These data are consistent with varying degrees of
tumor resistance to cytotoxic agents and radiotherapy,
and correlate with shortened survival and death. Thus
pathologic response status was a reasonable surrogateThe Journal of Thoracic and Cfor risk of recurrence and may be useful along with mo-
lecular characteristics in the future for selecting patients
for additional or alternative forms of therapy following
surgery.
Limitations of this study include its retrospective na-
ture, the confines of a single institutional study, and lim-
itations of the database. Hence, specific data points such
as cancer-specific death were not able to be obtained on
all patients. This limits the ability to determine with cer-
tainty that death during follow-up is entirely due to recur-
rence of tumor. The relatively small size of this study
does not allow for rigorous stratification, such as examin-
ing differences in outcomes between chemotherapeutic
agents and different doses of radiotherapy. In larger data-
bases, however, such as the Nationwide Inpatient Sample
and the Surveillance, Epidemiology, and End Results da-
tabases, these variables are either characteristically miss-
ing or erroneous. Ideally, to study outcomes such asardiovascular Surgery c Volume 138, Number 6 1315
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tient-oriented database would be needed. Because this
study spans 19 years and multiple examining pathologists,
we reported pathologic findings based on a simple stan-
dard of CR, PR, and NR rather than the more detailed de-
scriptor of percentage of viable cells in the specimen. A
final limitation of the study is that because of its retro-
spective nature, the time to recurrence (and location of re-
currences) could have been impacted by the fastidiousness
of monitoring.
The findings of this study, and others,16 suggest that not
all esophageal carcinomas are equal and that rather than
more aggressive chemotherapy regimens, or more inten-
sive radiation dosing schedules, efforts must be made to
target different tumors with chemotherapeutic agents to
which they are sensitive. This new era of ‘‘personalizing’’
or customizing chemotherapeutic and radiation regimens
to specific molecular targets in the primary tumor is
now upon us, and because of the success of the neoadju-
vant therapy approach in esophageal cancer, this is an ap-
propriate cancer model to test these innovations.
Importantly, this study emphasizes the critical role of neo-
adjuvant chemotherapy in ‘‘eliminating’’ distant disease
outside of the local surgery and radiation fields and offers
yet more evidence that ultimately the control of distant
disease is critical in preventing esophageal cancer recur-
rence. Patients who experience a CR to neoadjuvant ther-
apy have the best outcomes in terms of lowest incidence
of recurrence, longest disease-free survival, and longest
overall survival.
The authors would like to acknowledge the Hosler Family, the
Thorn Family, the family of Mr Robert Carollo, and the family of
Mrs Catherine Remmert whose generous contributions have sup-
ported this research.
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Discussion
Dr Michael Weyant (Aurora, Colo). Good morning. I would
like to first thank the Western for inviting me to discuss this paper,
and I would also like to thank the authors for sending me the man-
uscript well in advance.
In our evolution of the treatment of patients with locally ad-
vanced esophageal malignancy, trimodality therapy has emerged
as the standard of care in this group of patients, with preoperative
chemoradiation being the standard. What has emerged out of all
this is the 3 groups of patients that you illustrated so nicely here,
the patients with complete response responding better than either
the patients with partial response or those with no response.
Your work illustrates the patterns of recurrences, which is also
extremely valuable because it is work like this that will help guide
future studies regarding the therapy of these patients as well.
I just have 3 brief questions for you.
First, I would like to knowwhat your standard stagingmodalities
are in the pretreatment setting for guiding your therapy of these pa-
tients.
DrMeguid (Baltimore, Md). Although there has been an evolu-
tion of about 15 years between the first patients and our most recent
patients, currently we are obtaining high-resolution CT scans of all
patients. We are also increasingly using positron emission tomog-
raphy scans and endoscopic ultrasound to stage patients.
Dr Weyant. My second question ties into that, knowing that
you are using the modern staging modalities. In the manuscript
you sent me, in the characterizations of your preclinically staged
patients, you had 26 patients who were clinically staged as stage
IV and conversely you had a group of patients of 12, I believe,
who were stage I that you did not illustrate in your talk. The ques-
tions are, what is the rationale and what are the characteristics of
those patients in stage IV that actually led them to get surgery,
and then conversely, what is the rationale for the group of pa-
tients in stage I to get the neoadjuvant therapy and then surgery
as well?
Dr Meguid. I agree these are very valid points.
Those are all patients who got neoadjuvant therapy and surgery,
and included in our series. At our institution, we offer neoadjuvant
therapy and surgery to patients with Stage IVa disease.
These are limitations to our preliminary study, and we need to
resolve these before we pursue this as a publication.Surgery c December 2009
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SDrWeyant.The last question is, and you briefly alluded to the dif-
ference between squamous carcinomas and adenocarcinomas. There
is a general belief that they behave very differently and respond dif-
ferently to neoadjuvant therapy. Did you do any subset analysis look-
ing at the 2 subgroups regarding complete response and survival?
Dr Meguid. Yes, actually this is in the manuscript revised
since we sent it to you. In brief, the patients with nonresponding
squamous cell carcinoma did very poorly and died very rapidly,
whereas the patients with squamous cell carcinoma whom re-
sponded had relatively favorable outcomes, and have not yet
reached 50% mortality. The differences in patients with adenocar-
cinoma are less pronounced than this. Again, we have done a se-
ries of subanalyses and are currently trying to identify which
different relationships exist.
DrDavid Follette (Sacramento, Calif). That was a superbly pre-
sented paper. I am always pleased to see when studies validate other
work. The subset of your squamous cell carcinoma certainly vali-
dates some work from East Germany that showed in a group of pa-
tients showing complete response with squamous cell carcinomas
there was approximately 70% 5-year survival. I think your valida-
tion of that work is very important and in a way validates some of
your conclusions, notwithstanding the homework you are going to
do when you get back.
Having said that, it is like what we were talking about yesterday
with lung cancer. At Baltimore, do you do any restaging after neo-
adjuvant chemoradiation?
Dr Meguid.We do some restaging, mostly the 50% of our pa-
tients who get their neoadjuvant therapy at outside institutions. In
this study, we did not look at that restaging. We looked at patients’
preneoadjuvant staging and their postoperative pathologic staging
to make a comparison as to who was downstaged, who showed
no response, and who had a complete response.
Dr Follette. Because as you know, we have no prospective ran-
domized trials validating neoadjuvant treatment, but if we begin to
look—and Tom Rice has pointed this out to us on numerous occa-
sions. Nodal disease is really a poor indicator.
My second question, when you are talking about complete re-
sponse, you are talking about both the tumor and no positive nodes
in the surgical specimen?
Dr Meguid. That is correct. There is no evidence of disease in
the surgical specimen.
Dr Follette. I appreciate a very well-presented paper, and I be-
lieve your results are going to help all of us in the debate aboutThe Journal of Thoracic and Caneoadjuvant treatment and its value in that subset of patients who
show complete response.
Dr Robert Cerfolio (Birmingham, Ala). Very well presented.
Two quick questions, because I see the time is short. Do you
have maximum standardized uptake value data in the people who
got the positron emission tomography, the change in the maximum
standardized uptake value?
Dr Meguid. We do not have that data in our database.
Dr Cerfolio. So can I look forward then to seeing it in the man-
uscript?
Dr Meguid. No, it won’t be.
Dr Cerfolio. Okay, the second question is: I love to come to
these meetings because I learn stuff and I take it back. You heard
how I changed my practice with Dr Lowe’s article a few years
ago. How is this paper going to change my practice? What am I go-
ing to do differently?
DrMeguid. This may change what you tell your patients. If you
have female patients, if you have patients with squamous cell
esophageal adenocarcinoma, you may be able to tell them they
are more likely to show complete response than male patients or pa-
tients with adenocarcinoma. That is in the short run. In the long run,
I believe this is leading us more to look at tumor biology differences
and try to identify what we can do to appropriately target patients
with better chemotherapeutic regimens so that we can ultimately
have more clinical complete responses as opposed to just continu-
ing the same trends we have been doing.
Dr James Stewart (Colorado Springs, Colo). As a 20-year vet-
eran of advocating neoadjuvant chemoradiation for esophageal
cancer, we noticed about 15 years ago that patients showing partial
response just did not do as well, and although I have not published
any information, we developed some postoperative treatment strat-
egies for those patients and wondered if you had also adopted
something similar.
Dr Meguid. That is an interesting observation. In fact, patients
showing partial response do almost as poorly as those showing no
response, such that in the abstract in the meeting program, we com-
bined them because they have similarly dismal outcomes. Our pa-
tients—about 20% of all the groups, with no statistically significant
difference between the groups—received postoperative chemother-
apy. I do not believe it resulted in a difference in the 3 treatment
groups. As of yet, we have not been able to identify, up front, pa-
tients whom are going to have partial response versus those going
to have no response, unfortunately.rdiovascular Surgery c Volume 138, Number 6 1317
